Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) just unveiled an announcement.
CARsgen Therapeutics Holdings Ltd. held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed. Key decisions included the re-election of directors, the re-appointment of Ernst & Young as auditors, and the granting of mandates to the board for share issuance and repurchase. These resolutions indicate strong shareholder support and strategic continuity, potentially enhancing the company’s operational capabilities and market positioning.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biotechnology company primarily focused on the development of innovative CAR-T cell therapies for the treatment of cancer. The company operates within the pharmaceutical and biotechnology industry, with a market focus on advancing cancer treatment options through cutting-edge immunotherapy solutions.
Average Trading Volume: 5,129,581
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.91B
See more data about 2171 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue